Form 4 for CRL Charles River Laboratories
Accepted 2023-01-30 00:00:00 ET · period of report 2023-01-27 · accession 0001127602-23-002672 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-30 | 2023-01-27 | CRL | Girshick Birgit | COO, Corp. Executive VP | A - Grant | $0.00 | +8,435 | 44.2K | +24% | $0 | |
| 2023-01-30 | 2023-01-27 | CRL | Girshick Birgit | COO, Corp. Executive VP | F - Tax | $244.29 | -3,153 | 41.0K | -7% | -$770.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-27 | A | A | 8,435 | $0.00 | 44,191 | D | — | — | (F1) Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 29, 2020. |
| 2 | Common | Common Stock | 2023-01-27 | F | D | 3,153 | $244.29 | 41,038 | D | — | — |